What Is GLP-1? Benefits, Research & Safety
A naturally occurring gut hormone that regulates glucose metabolism and appetite, serving as the basis for major obesity and diabetes medications.
UK summary: Endogenous gut hormone — not a medicine per se, but the basis of UK-licensed GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide). Native GLP-1 is too short-acting to be useful as a drug; this page is educational background.
Quick Facts
Overview
GLP-1 — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
Endogenous gut hormone — not a medicine per se, but the basis of UK-licensed GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide). Native GLP-1 is too short-acting to be useful as a drug; this page is educational background.
02Human evidence grade
03Preclinical evidence grade
04Regulatory status
- UK: Native GLP-1 not used; GLP-1 agonists are approved medications.
- EU: Multiple GLP-1 receptor agonists approved for diabetes and obesity.
- Notes: The biological understanding of GLP-1 has led to the development of highly successful medications including semaglutide, liraglutide, and others.
05Approved medical uses
None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)
06Unapproved / promotional claims
- Oral 'GLP-1 boosters' raise natural GLP-1 levels and produce weight loss.
- Bitter-melon, berberine, or natural GLP-1 supplements substitute for semaglutide.
- Native GLP-1 peptide is available for injection and works like Ozempic.
07Common internet claims
- Marketed in supplements as 'natural GLP-1' or 'GLP-1 activators'.
- Sold by some online retailers as research-only injectable GLP-1.
- Promoted in wellness blogs as a lifestyle alternative to prescription GLP-1 agonists.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “GLP-1 supplements raise your natural GLP-1 levels” | E | No | High | Native GLP-1 has a half-life of minutes; oral 'GLP-1 boosting' supplements have no evidence base. Use a licensed GLP-1 receptor agonist via a UK prescription if clinically indicated. |
| “GLP-1 is the same as Ozempic” | E | No | High | Ozempic is semaglutide — a chemically modified analogue with a half-life of about a week. Native GLP-1 is the underlying biology, not the medicine. |
09Safety uncertainty score
Safety profile partly characterised; some signals from observational or preclinical data.
10Known adverse signals
- Native GLP-1 is endogenous, with minutes-long half-life; the underlying biology is well characterised.
- Injectable 'native GLP-1' from grey-market sources has unverified identity and sterility.
- Supplement-route 'GLP-1 boosters' have no consistent safety profile because their actual mechanisms vary.
11Drug-interaction uncertainty
Drug-interaction picture documented in the prescribing information.
12Anti-doping status
13UK legal position
Native GLP-1 not used; GLP-1 agonists are approved medications.
14EU legal position
Multiple GLP-1 receptor agonists approved for diabetes and obesity.
15What this page cannot tell you
- Whether any oral 'GLP-1 booster' supplement actually raises GLP-1 in your body.
- Whether injectable native-GLP-1 products contain GLP-1 or a different compound.
- How injectable native GLP-1 would differ pharmacokinetically from licensed analogues (it would be far too short-acting to be useful).
16Last reviewed
17Citation quality score
18Research gaps
- Lifestyle interventions (diet composition, meal timing) that meaningfully modulate endogenous GLP-1 response are studied but effects are small versus pharmacological GLP-1 agonism.
19Safer alternatives / established care pathways
- Licensed GLP-1 receptor agonist (semaglutide, tirzepatide, liraglutide) via UK prescriber where clinically indicated.
- Lifestyle interventions (Mediterranean-style diet, protein-adequate meals, regular exercise) that support normal incretin response.
- NHS Tier 2 / Tier 3 weight management programmes for structured behaviour change.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Am I a candidate for a licensed GLP-1 receptor agonist (semaglutide, tirzepatide, liraglutide)?
- What lifestyle approaches enhance natural incretin response?
Discovery & History
Mechanism of Action
Researched Benefits
Based on preclinical and clinical research findings:
- 1Glucose-dependent insulin secretion (low hypoglycaemia risk)
- 2Improved glycaemic control in type 2 diabetes
- 3Appetite suppression and weight loss
- 4Delayed gastric emptying contributing to satiety
- 5Potential beta cell preservation
- 6Cardiovascular benefits observed with GLP-1 agonists
Claim vs Evidence
How popular claims about GLP-1 stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “GLP-1 supplements raise your natural GLP-1 levels” | E | No | High | Native GLP-1 has a half-life of minutes; oral 'GLP-1 boosting' supplements have no evidence base. Use a licensed GLP-1 receptor agonist via a UK prescription if clinically indicated. |
| “GLP-1 is the same as Ozempic” | E | No | High | Ozempic is semaglutide — a chemically modified analogue with a half-life of about a week. Native GLP-1 is the underlying biology, not the medicine. |
Theoretical Dosing & Protocols
| Theoretical Dosage | Native GLP-1 is not used therapeutically due to short half-life |
| Frequency | N/A for native GLP-1 |
| Duration | N/A |
| Notes | Native GLP-1 is not practical for therapeutic use. Instead, GLP-1 receptor agonists (semaglutide, liraglutide) or DPP-4 inhibitors are used to achieve GLP-1-like effects. |
Administration Routes
Routes studied in research settings (educational only):
- Native GLP-1 would require continuous infusion (not practical)
- GLP-1 analogues: subcutaneous injection or oral (for semaglutide)
| Half-Life | Stability |
|---|---|
| 1-2 minutes for native GLP-1 (rapidly degraded by DPP-4) | Native GLP-1 is highly unstable; analogues have been engineered for stability |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Not applicable for native GLP-1 (not used therapeutically)
- See semaglutide and liraglutide entries for GLP-1 agonist side effects
Rare Risks & Concerns
- GLP-1 agonist class effects include pancreatitis risk, gallbladder disease
Contraindications
- See specific GLP-1 agonist entries for contraindications
UK & EU Regulatory Context
🇬🇧 United Kingdom
Native GLP-1 not used; GLP-1 agonists are approved medications.
🇪🇺 European Union
Multiple GLP-1 receptor agonists approved for diabetes and obesity.
Clinical Studies Summary
GLP-1: From the Discovery of Incretin Hormones to Therapeutic Applications
Comprehensive review of GLP-1 biology and the development of GLP-1-based therapies.
Looking for GLP-1?
Source research-grade GLP-1 from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about GLP-1
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Am I a candidate for a licensed GLP-1 receptor agonist (semaglutide, tirzepatide, liraglutide)?
- What lifestyle approaches enhance natural incretin response?
UK regulatory & safety context
Related Peptides
Semaglutide
A GLP-1 receptor agonist approved for type 2 diabetes and obesity treatment, representing one of the most significant advances in weight management pharmacotherapy.
Learn moreLiraglutide
An earlier GLP-1 receptor agonist approved for diabetes and weight management, offering once-daily dosing with proven efficacy and safety.
Learn moreTirzepatide
A first-in-class dual GLP-1 and GIP receptor agonist achieving unprecedented weight loss of up to 22% in clinical trials, approved for type 2 diabetes and obesity treatment.
Learn more